AU2002328093B2 - Pharmaceutical compositions comprising polysaccharide conjugates for inhibiting the metastsis or preventing the recurrence of maligant tumor - Google Patents
Pharmaceutical compositions comprising polysaccharide conjugates for inhibiting the metastsis or preventing the recurrence of maligant tumor Download PDFInfo
- Publication number
- AU2002328093B2 AU2002328093B2 AU2002328093A AU2002328093A AU2002328093B2 AU 2002328093 B2 AU2002328093 B2 AU 2002328093B2 AU 2002328093 A AU2002328093 A AU 2002328093A AU 2002328093 A AU2002328093 A AU 2002328093A AU 2002328093 B2 AU2002328093 B2 AU 2002328093B2
- Authority
- AU
- Australia
- Prior art keywords
- glycyl
- glycine
- group
- polysaccharide
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Description
WO 03/015826 PCT/JP02/08309
DESCRIPTION
PHARMACEUTICAL COMPOSITIONS COMPRISING POLYSACCHARIDE CONJUGATES FOR INHIBITING THE METASTASIS OR PREVENTING THE RECURRENCE OF MALIGNANT TUMOR TECHNICAL FIELD The present invention relates to a pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of a malignant tumor. More particularly, the present invention relates to a pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of a malignant tumor, which comprises as the active ingredient a polysaccharide derivative comprising a polysaccharide having a carboxyl group bound to an active substance having an anti-tumor activity, for example, a camptothecin derivative of the formula or (II) as mentioned below, via an amino acid or a peptide consisting of 2 to 8 amino acids which are the same or different, or a salt thereof.
BACKGROUND ART Malignant tumors are one of the main causes of death in the developed countries, and the majority of malignant tumors related deaths are due to metastasis into distant organs or recurrence accompanied by metastasis to distant WO 03/015826 PCT/JP02108309 2 organs after a topical therapy. The metastasis to distant organs may be caused by hematogenous metastasis or lymphogenous metastasis, and it is known that a patient having lymphogenous metastasis has a high risk of recurrence of a malignant tumor after topical therapy. The main organs of recurrence are brain, lung, liver, and bone.
Especially, a tumor in digestive apparatus, for example, colon cancer from which a large number of patients are suffered, may often invade and spread to the liver, and a breast cancer and a lung cancer as well often invade and spread to the liver. Further, a lymphoma and a lymphatic leukemia may spread mainly to the lymph system, and it has been reported that the metastasis to liver was observed in high rate by autopsy.
In order to inhibit the recurrence including the metastasis to distant organs such a metastasis to the liver and to prolong life, a chemotherapy, etc. is employed as a supportive care after a topical therapy, but the chemotherapy has a potent toxicity and cannot be used for chronic administration. In addition, it has scarcely been reported that the lifetime is more prolonged by a supportive care of chemotherapy than a topical therapy alone. For example, in the trials of post-surgery chemotherapy for the patient who is the subject of surgery of advanced gastric cancer, one of the cancers of digestive -3organs, clinical tests of various agents for anti-malignant tumors have been tried, but any therapeutic method exhibiting a remarkably better survival rate than a surgery alone has not been established yet.
Under these circumstances, it has been desired to find a new agent effective in inhibiting recurrence or in prolonging life after topical therapy, which is applicable to the lymph node and the distant organs of metastasis with little side effects, and is suitable for chronic administration.
On the other hand, WO 94/19376, WO 97/46260, WO 97/38727, JP-A- 10-72467 and JP-A-10-95802 disclose a polysaccharide derivative comprising a polysaccharide bound to an active substance having an anti-tumor activity via an amino acid or a peptide.
However, these publications disclose the use of these polysaccharides in the treatment of cancers by accumulating at the tumor site and killing the tumor cells, but never indicate activities of inhibiting metastasis or preventing recurrence of a malignant tumor.
The discussion of the background to the invention herein is included to explain the context of the invention. This is not to be taken as an admission that any of the material referred to was published, known or part of the common general knowledge in Australia as at the priority date of any of the claims.
DISCLOSURE OF THE INVENTION An object of the present invention is to provide a novel pharmaceutical composition for inhibiting the metastasis or preventing the recurrences of a malignant K W:MocumentsDo Not DeleteAmendmentsURN712443-Ido 4 August 2004 WO 03/015826 PCT/JP02/08309 4 tumor.
The present inventors have intensively studied, and have found that a polysaccharide derivative comprising a polysaccharide having a carboxyl group bound to an active substance having an anti-tumor activity via an amino acid or a peptide exhibits an excellent effect in the inhibition of metastasis and/or prevention of recurrence of a malignant tumor, and have accomplished the present invention. That is, the present invention relates to pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of a malignant tumor, which comprises as the active ingredient a polysaccharide derivative comprising a polysaccharide having a carboxyl group bound to an active substance having an anti-tumor activity via an amino acid or a peptide consisting of 2 to 8 amino acids which are the same or different, or a salt thereof.
BRIEF DESCRIPTION OF DRAWINGS Fig 1 shows the lapsed days after implantation of tumor and the number of survived animals in M 5076 liver metastatic models.
BEST MODE FOR CARRYING OUT THE INVENTION The polysaccharide having a carboxyl group of the WO 03/015826 PCT/JP02/08309 present invention includes the same ones as those disclosed in the above mentioned WO 94/19376 and WO 97/46260, and includes polysaccharide having originally carboxyl groups in the structure thereof hyaluronic acid, pectic acid, alginic acid, chondroitin, heparin, etc.), and polysaccharides having originally no carboxyl group pullulan, dextran, mannan, chitin, mannoglucan, chitosan, etc.) but being introduced thereto carboxyl groups, and polysaccharides having originally no carboxyl group in the structure thereof but being introduced thereto carboxyl groups after polyalcohol formation polysaccharide polyalcohol having a carboxyl group).
The polysaccharide having originally no carboxyl group but being introduced thereto a carboxyl group means ones that are prepared by substituting a hydrogen atom of a part or all of hydroxyl groups of polysaccharides having originally no carboxyl group with a carboxy-C, 4 alkyl group.
In the present invention, the polysaccharide having a polysaccharide includes one that are prepared by treating a polysaccharide originally having no carboxyl group with a reducing agent, and then followed by substituting a hydrogen atom of a part or all of hydroxyl groups of the resultant with a carboxy-C, 4 alkyl group.
The polysaccharide polyalcohol having a carboxyl group includes, for example, a carboxy-C,.
4 alkyl-polysaccharide WO 03/015826 PCT/JP02/08309 6 polyalcohol which is prepared by treating a polysaccharide originally having no carboxyl group successively with sodium periodate and sodium borohydride by the method disclosed in WO 97/46260 to give a polysaccharide polyalcohol, which is further treated with a halogenated C,.4 alkylcarboxylic acid.
The alkyl moiety of the carboxyl-C, 4 alkyl group which substitutes a hydrogen atom of the hydroxyl groups of the above polysaccharide (including a polysaccharide polyalcohol) may be either a straight chain alkyl group or a branched chain alkyl group.
Preferable carboxy-C 1 _4 alkyl group is, for example, carboxymethyl group, 1-carboxyethyl group, 3-carboxypropyl group, 1-methyl-3-carboxypropyl group, 2-methyl-3-carboxypropyl group, 4-carboxybutyl group, etc., and carboxymethyl group is more preferable.
In the present invention, the polysaccharide having a carboxyl group is preferably carboxy-C 1 4 alkyldextran or carboxy-Ci.
4 alkyldextran polyalcohol, and carboxyl-C 1 4 alkyldextran is especially preferable.
The degree of polyalcohol formation (by the successive oxidation with sodium periodate and reduction with sodium borohydride) in the step of preparing the carboxy-C 1 _4 alkyl-polysaccharide polyalcohol as mentioned above is not specified, but the intermediate polysaccharide polyalcohol WO 03/015826 PCT/JP02/08309 7 is preferably one being obtained by treating a polysaccharide under possible conditions for substantially almost completely forming polyalcohol.
Moreover, in the present invention, the polysaccharide having a carboxyl group is preferably carboxymethylated dextran or carboxymethylated dextran polyalcohol, and among these polysaccharides, particularly dextran having an average molecular weight of 20,000 to 500,000 is more preferable, and dextran having an average molecular weight of 50,000 to 350,000 is most preferable (said average molecular weight being determined by Gel permeation chromatography (GPC) method, Shinseikagaku, Jikken Koza, vol. 20, p. 7, Tokyo-Kagaku-Dojin, November 5, 1991).
When introducing a carboxylalkyl group into polysaccharides, the degree of the introduction thereof is expressed by "degree of substitution" which is defined by a number of carboxylalkyl groups (including groups of peptide chain being introduced by these groups) per a sugar residue.
That is expressed by the following equation.
Number of carboxyalkyl groups Degree of in the molecule Substitution Total number of sugar residues in the molecule When the carboxylalkyl group is carboxymethyl group, the degree of substitution is occasionally expressed by the degree of carboxymethylation (CM-degree).
WO 03/015826 PCT/JP02/08309 8 When the polysaccharide is dextran, the degree of substitution thereof is preferably in the range of 0.3 to 0.8. When the polysaccharide is dextran polyalcohol, the degree of substitution is preferably in the range of 0.3 to The amino acid or peptide of the present invention plays a role of spacer existing between a polysaccharide having a carboxyl group and an active substance having an anti-tumor activity, and the amino acid or amino acid forming said peptide includes both natural amino acids and synthetic amino acid (including D-amino acids, L-amino acids, a mixture thereof), and also includes either neutral amino acids, basic amino acids or acidic amino acids.
Moreover, the amino acid of the present invention may be not only a-amino acid but also p-amino acids, y-amino acids, e-amino acids, etc.
Examples of the amino acids are glycine, a-alanine, Palanine, valine, leucine, isoleucine, serine, threonine, systeine, methionine, aspartic acid, glutamic acid, lysine, citrulline, arginine, phenylalanine, tyrosine, histidine, tryptophan, proline, hydroxyproline, y-aminobutyric acid, E-aminocaproic acid, etc.
The peptide of the present invention includes ones consisting of 2 to 8 amino acids, preferably 2 to 5 amino acids, which are the same or different. Examples of the WO 03/015826 PCT/JP02/08309 9 peptides are glycyl-glycyl-L- or D-phenylalanyl-glycine, glycyl-glycine, glycyl-glycyl-glycine, glycyl-glycylglycyl-glycine, glycyl-glycyl-glycyl-glycyl-glycine, L- or D-phenylalanyl-glycine, L- or D-tyrosyl-glycine, L- or Dleucyl-glycine, L- or D-phenylalanyl-citrulline and L- or D-valyl-citrullin (the N-terminus of these peptides is introduced onto the carboxyl group of a polysaccharide).
Among these peptides, glycyl-glycyl-L- or D-phenylalanyl-glycine, glycyl-glycine, glycyl-glycyl-glycine, glycyl-glycyl-glycyl-glycine, glycyl-glycyl-glycyl-glycylglycine, and L- or D-phenylalanyl-glycine are preferable.
The active substance having an anti-tumor activity of the present invention may include various compounds being known as an anti-tumor agent, and may be either cytotoxic agents or cytostatic agents. The cytotoxic agent is preferably camptothecin derivatives and taxane derivatives, and the cytostatic agent is preferably angiogenesis inhibitors, EGF receptor inhibitors. More preferably, the cytotoxic agent is camptothecin derivatives, and the cytostatic agent is angiogenesis inhibitors.
Examples of camptothecin derivatives are compounds disclosed in JP-A-10-72467 of the formula WO 03/015826 PCT/JP02/08309 R O 1 NO X'-Alk-O- (I) N 0
H
5 C2 OH wherein R 1 is a substituted or unsubstituted lower alkyl group, X' is a group of the formula: -NHR 2
(R
2 is a hydrogen atom or a lower alkyl group) and Alk is a straight chain or branched chain Ci_, alkylene group having optionally an oxygen atom in the chain thereof. Among them, preferable compound is 10-(3'-aminopropyloxy)-7-ethyl-(20S)camptothecin.
Other examples of camptothecin derivatives are compounds disclosed in JP-A-10-95802 of the formula (II):
R
3
R
2 0
(II)
R
5 R
H
5 C2 OH wherein two groups of R 2 to R 6 being adjacent each other combine to form a lower alkylene group, and one of the carbon atoms of said lower alkylene group is substituted by an amino group, and the remaining three groups of R 2 to R 6 are a hydrogen atom, a lower alkyl group or a halogen atom.
Among them, preferable compound is (IS, 9S)-l-amino-9ethyl-5-fluoro-2,3-dihydro-9-hydroxy-4-methyl-lH,12Hbenzo[de]pyrano[3',4':6,7]indolidino[1,2-b]quinoline- WO 03/015826 PCT/JP02/08309 11 10,13(9H,15H)-dione, etc.
Examples of taxane derivatives are Taxol, Taxotere, 13-[(2'R,3'R)-3'N-t-butyloxycarbonyl-3'-cyclopropyl]-10deacetyl-baccatin III, etc.
In the active ingredient of the present invention, the ratio of the polysaccharide and the active substance having an anti-tumor activity may be selected according to the kinds of the polysaccharide to be used, but when the polysaccharide is dextran or dextran polyalcohol, then the content of the active substance having an anti-tumor activity is preferable in the range of 0.1 to 20 by weight, more preferably in the range of 2 to 10 by weight, based on the whole weight of the active ingredient.
Among the active ingredients of the present invention, preferable ones are polysaccharide derivatives or a salt thereof wherein an amino acid or a peptide consisting of 2 to 8 amino acids which are the same or different are introduced into a part or all of the carboxyl groups of the polysaccharide having a carboxyl group through an acidamide bond, and the remaining part or all of the amino groups or carboxyl groups which do not participate in the binding to the carboxyl groups of the above peptide are bound to the carboxyl groups, amino groups or hydroxyl groups of the active substance having an anti-tumor activity through an acid-amide bond or ester bond.
WO 03/015826 PCT/JP02/08309 12 Especially preferable active ingredient is a polysaccharide derivative, wherein the polysaccharide having an carboxyl group is carboxymethylated dextran, the active substance having an anti-tumor activity is 10-(3'aminopropyloxy)-7-ethyl-(20S)-camptothecin, and the peptide is glycyl-glycyl-glycine, or a salt thereof. Especially preferable one is a polysaccharide derivative wherein the polysaccharide having a carboxyl group is carboxymethylated dextran having an average molecular weight of 60,000 to 200,000, and the degree of carboxymethylation thereof is in the range of 0.3 to 0.8, or a salt thereof.
Other preferable active ingredient is a polysaccharide derivative wherein the polysaccharide having a carboxyl group is a carboxy-C 1 .4 alkyldextran polyalcohol, the active substance having an anti-tumor activity is (1S, 9S)-1amino-9-ethyl-5-fluoro-2,3-dihydro-9-hydroxy-4-methyl- 1H,12H-benzo[de]pyrano[3',4':6,7]indolidino[1,2-b]quinoline-10,13(9H,15H)-dione, and the peptide is glycylglycyl-L- or D-phenylalanyl-glycine, or a salt thereof, and especially preferable ones are a polysaccharide derivative or a salt thereof wherein the polysaccharide having a carboxyl group is carboxy-C 1 alkyldextran polyalcohol having an average molecular weight of 200,000 to 400,000, and the degree of the substitution thereof is in the range of 0.3 to WO 03/015826 PCT/JP02108309 13 The polysaccharide derivative or a salt thereof of the.
active ingredient of the present invention may be prepared according to the methods disclosed in WO 94/19376, WO 97/46260, WO 97/38727, JP-A-10-72467, and JP-A-10-95802.
The pharmaceutical composition of the present invention may highly accumulate at the site such as lymph node or the liver to which cancers may spread, can release an active substance at an appropriate rate so that the active substance hardly affects on the normal cells and suppressively acts on the growth of tumor cells, and hence, the pharmaceutical composition of the present invention is useful in the inhibition of metastasis or prevention of reoccurrence of a malignant tumor. Especially, the pharmaceutical composition of the present invention is useful in the inhibition of lymph node metastasis or liver metastasis, particularly useful in the inhibition of lymph node metastasis. Further, among lymph node metastasis, the present pharmaceutical composition is useful in the inhibition of metastasis in lymph node from the colon, or metastasis in lymph node from the lung.
In addition, the present pharmaceutical composition may exhibit its effects not only before the onset of metastasis but also after the onset of metastasis.
Therefore, the present pharmaceutical composition is also useful in the inhibition of metastasis or prevention of WO 03/015826 PCT/JP02108309 14 reoccurrence of a malignant tumor after a topical therapy surgery, radiation therapy, thermotherapy, cryotherapy, laser burning therapy, etc.). Moreover, the present pharmaceutical composition is also suitable for repetitive dosing for long time, and can be employed together with a topical therapy.
The present pharmaceutical composition is preferably administered parenterally intravenous injection), and is usually administered in the form of a liquid preparation such as solution, suspension, emulsion, etc.
The present pharmaceutical composition is preferably formulated in the form of an injection or drip infusion by using distilled water for injection, physiological saline solution, aqueous glucose solution.
The dosage of the present pharmaceutical composition may vary according to the administration methods, age, weight or conditions of the patients, etc., but it is usually in the range of 0.002 to 50 mg/kg, more preferably in the range of 0.01 to 5 mg/kg, in single dose, converted into an amount of the active substance.
In the present specification, the lower alkyl group and the lower alkylene group may be ones having 1 to 6 carbon atoms, preferably ones having 1 to 4 carbon atoms, and the halogen atom is fluorine atom, chlorine atom, bromine atom, iodine atom, etc.
WO 03/015826 PCT/JP02/08309
EXPERIMENTS
Experiment 1 (M 5076 liver metastatic models) One million of M 5076 cells (mouse ovarian sarcoma cells) were implanted into BDF1 male mice (5-weeks old, 8 animals per group) at the tail vein. A test compound (Compound A; the compound obtained in Preparation 1 as described below and Irinotecan (CPT-11)) was dissolved in a physiological saline solution, and each amount as indicated in Table 1 as mentioned below was administered intravenously to the mice on the 4th, 8th and 12th day after the implantation, and the mice were observed for 120 days after the implantation of tumor. In the control group (untreated with test compound), only a physiological saline solution was administered. The survival time (days) was measured in both the test compound-treated groups and the control group, and the prolongation rate of survival was calculated according to the following equation. The results are shown in Table 1 and Fig. 1.
WO 03/015826 PCT/JP02/08309 16 (Survival days in the test Prolongation rate compound-treated group X 1 of survival Survival days in the control group Table 1 Prolongation Dose Survival Standard at o (mg/kg) days error survival Control 15.00 1.24 Compound A 12.5 37.57 5.27 150.5 43.13 5.98 187.5 48.71 5.33 224.8 Irinotecan 80 22.50 0.5 50.0 As is shown in Table 1, the compound obtained in Preparation 1 as mentioned below (Compound A) exhibited an excellent activity of prolonging lifetime in M5076 liver metastatic models. Meanwhile, Irinotecan is not known as an agent for inhibiting the metastasis or preventing the reoccurrence of a malignant tumor, but it was merely tested as a drug of camptothecin derivatives.
Experiment 2 (HT-29 metastatic models) A segment (2 mm 2 of HT-29 cells (human colon cancer) was implanted into the vermiform appendix of 100NCr nu/nu female mice (5 to 6 weeks old, 10 animals per group). A test compound (Compound A; the compound obtained in Preparation 1 as mentioned below, Compound B; the compound obtained in Preparation 4 as mentioned below, and WO 03/015826 PCT/JP02/08309 17 Irinotechan (CPT-11)) was dissolved in a physiological saline solution, and each amount as indicated in Table 2 as mentioned below was administered intravenously to the mice on the 15th, 19th, 23rd and 25th day after the implantation of tumor. On the other hand, in the control group (untreated with test compound), only a physiological saline solution was administered. The presence or absence of the metastasis of each organ was checked on the 84th day after the implantation of tumor. The results are shown in the following Table 2.
Table 2 Other N .umber of number Lmhnode Liver Lung ogn** animals with Group of Lpho an* metastasis aias MI* MI* MI* MI* Compound A1. 0 <00 mg/kg) 10 0 <0.01 0 1.0 0 0.21 0 1.0 <.1 Compound A2 00 (2 gk)10 1 <0.01 0 1.0 1 0.5B 0 1.0 2 .0 mg/kg) compound A8 mg/kg) 10 8 10 0 1.0 1 105 2 1.0 6 03 Compound B mg/kg) 10 0 <0.01 0 1.0 0 0.21 0 1.0 0 <0.01 Compound B1. 6 03 mg/kg) 10 6 0.30 1 1.0 1 0.58 1 10 6 0.
Irinotecan 10 7 0.58 0 1.0 1 0.58 1 1.0 7 0.58 mg/kg) Irinotecan 10 9 1.0 2 1.0 2 1.0 0 1.0 9 mg/kg) Control 10 9 1 3 1 9 MI means Metastatic Incidence P means standard derivation, where test.
all treated groups compared to Control by Fischer exact Including Diaphragm, Abdominal cavity and Thoracic cavity.
Dosage converted into 10- -aminopropyloxy) -7-ethyl- (20S) -camnptothecin Dosage converted into (IS, 9S) 1-amino-9 -ethyl -5 -flucro-2, 3-dihydro-9-hydroxy-4-methyl- 1H,12H-benzo[de]pyrano[3'1,4':6,7)indolidino[1,2-b]quinolinelO0,13 C9H,15H)-dione WO 03/015826 PCT/JP02/08309 19 Experiment 3 (HT-29 metastatic models) A segment (2 mm 2 of HT-29 cells (human colon cancer) was implanted into the vermiform appendix of 100NCr nu/nu female mice (5 to 6 weeks old, 10 animals per group).
Since the lymph node metastasis was observed on the 49th day after the implantation of tumor, a test compound (Compound A; the compound obtained in Preparation 1 as mentioned below, and Irinotechan (CPT-11)) was dissolved in a physiological saline solution, and each amount as indicated in Table 3 as mentioned below was administered intravenously to the mice on the 51st, 55th, 59th, and 63rd day after the implantation of tumor. On the other hand, in the control group (untreated with test compound), only a physiological saline solution was administered. The presence or absence of the metastasis of each organ was checked on the 84th day after the implantation of tumor.
The results are shown in the following Table 3.
Table 3 Other Number of Number Lymph node Liver Lung organs*** animals with Group of metastasis animals MI* MI* MI* MI*
P**
Compound A Compound A 10 0 <0.01 0 1.0 0 0.21 2 1.0 2 <0.01 mq/kg) Compound A 10 2 <0.01 0 1.0 0 0.21 1 1.0 3 <0.01 Irinotecan Irinotecan 10 8 1.0 1 1.0 0 0.21 1 1.0 8 mg/kg) Control 10 9 1 3 1 9 MI means Metastatic Incidence P means standard derivation, where all treated groups compared to Control by Fischer exact test.
Including Diaphragm, Abdominal cavity and Thoracic cavity.
Dosage converted into 10-(3'-aminopropyloxy)-7-ethyl-(20S)-camptothecin WO 03/015826 PCT/JP02/08309 21 Experiment 4 (H460 metastatic models) A segment (2 mm 2 of H460 cells (human lung cancer) was implanted into the left lung of 100NCr nu/nu female mice (5 to 6 weeks old, 10 animals per group). Since the metastasis was observed on the 14th day after the implantation of tumor in another control group, a test compound (Compound A; the compound obtained in Preparation 1 as mentioned below, Compound B; the compound obtained in Preparation 4 as mentioned below, and Irinotechan (CPT-11)) was dissolved in a physiological saline solution, and each amount as indicated in Table 4 as mentioned below was administered intravenously to the mice on the 14th, 18th, 22nd and 26th day after the implantation of tumor. On the other hand, in the control group (untreated with test compound), only a physiological saline solution was administered. The presence or absence of the metastasis of each organ was checked on the 36th day after the implantation of tumor. The results are shown in the following Table 4.
Table 4 Number of number Lymph node Liver Lung animals with Group of metastasis animals Compound A 1 0 10 0 05 00 mg/kg) 10 1 <.1010005 00 Compound A2 0.5 0 10 2 05 3 024 Co0mpound A* 10 1 <0.01 0 1.0 0 0.54 1 0.024 Compound A Compound B 1 2 0.05 0 1.0 1 1.0 2 0.06 mg/kg) Compound B 1 00 g 12 0.501.0 0 105 1 0.02 mg/kg) 1 00 .4 100 Irinotecan 10 0 <0.01 0 1.0 1 1.0 1 0.02 mg/kg) Trinotecan 10 2 0.05 0 1.0 0 0.54 2 0.06 mg/kg) Control 20 13 0 2 12 MI means Metastatic Incidence P means standard deri test.
vation, where all treated groups compared to Control by Fischer exact Dosage converted into 10- -aminopropyloxy) -7-ethyl- (203) -camptothecin ***:Dosage converted into (1S, 9S) -1 -amino- 9-ethyl- 5-f luoro-2, 3-dihydro-9-hydroxy-4-methyi- 1H,12H-benzo~de]pyrano[3',4':,7]inlOidino[1,2-b]quinoline-10,13( 9 H,1H)diole WO 03/015826 PCT/JP02108309 23
PREPAPALTIONS
Preparation 1 Preparation of CM-dextran-7-ethyl-10- (glycyl-glycylglycylamino) propyloxy (20S) -can'ptothecin: CM-Dextran-(GIY) 3
-NH-(CH
2 3 -O 0~ N 0 (CM-Dextran means carboxymethyldextran, hereinafter, the same) 10- (3'-Aminopropyloxy) -7-ethyl- (20S) -camptothecin hydrochloride (500 mg) was dissolved in acetonitrile ml), and thereto were successively added t-butoxycarbonyl glycyl-glycyl-glycine (345 mg), N-methylmorpholine (121 mg) 1 N-hydroxybenzotriazole (161 mg) and 1-(3-dimethylaininopropyl)-3-ethylcarbodiimide hydrochloride (228 mg), and the mixture was stirred overnight. The precipitated product was collected by filtration, purified by silica gel column chromatography to give pale yellow foamy powder, which was recrystallized from n-propanol to give 7-ethyl-l0-[3'-(tbutoxycarbonyl-glycyl-glycyl-glycylamino) propyloxy] -(20S) camptothecin (663 mg) as colorless crystals.
157-1591C.
7-Ethyl-l0-[3'- (t-butoxycarbonyl-glycyl-glycyl- (3.86 g) was WO 03/015826 PCT/JP02/08309 24 emulsified in purified water (64 ml), and thereto was added 6N aqueous hydrochloric acid solution (32 ml), and the mixture was reacted at room temperature under stirring for 2 hours. The solvent was concentrated, and thereto was added n-propanol to precipitate powdery product. The resulting powdery product was collected by filtration, and recrystallized from aqueous n-propanol to give [3'-(glycyl-glycyl-glycylamino)propyloxy]-(20S)camptothecin hydrochloride (2.56 g) as yellow crystals.
CM-Dextran sodium salt (CM-degree 0.44, 50 g) was dissolved in water (2.5 liters), and the pH value thereof was adjusted to pH 5.0 with 0.2N aqueous hydrochloric acid solution under stirring at 15 0 C, and thereto was added 7ethyl-10-[3'-(glycyl-glycyl-glycylamino)propyloxy]-(20S)camptothecin hydrochloride (4.01 To the mixture was added 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (50 during which the pH value of the reaction solution was kept at 5.0-5.5 with 0.2N hydrochloric acid. The mixture was reacted at 150C under stirred for one hour, and diluted to the total volume of liters with purified water. While the pH value was kept at over pH 4.0, the low molecule fractions were removed by using an ultrafiltration module (ACP-1010, manufactured by Asahi Kasei Industries, Ltd.), and the pH value thereof was adjusted to pH 8 with 0.1N aqueous sodium hydroxide WO 03/015826 PCT/JP02/08309 solution, and then subjected to ion-exchange resin MSC-1 (Na-type, manufactured by Dowex). The fractions containing the desired compounds are concentrated, and filtered through a filter (0.45 pm). The resultant was mixed with ethanol (10 liters) with stirring, and thereto was added dropwise 3M brine (40 ml) under stirring. The resulting precipitates were collected by filtration, and dissolved in purified water (21 liters). The pH value of the solution was adjusted to pH 4.0 with 0.2N aqueous hydrochloric acid solution, and subjected again to ultrafiltration during which the pH value was kept at pH 4.0. The solvent was concentrated to the total volume of 1.5 liter, and filtered through a filter (0.45 pm). The resultant was mixed with ethanol (9 liters), and thereto was added dropwise 3M brine (35 ml) under stirring. The resulting precipitates were collected by filtration, and washed successively with ethanol and acetone, concentrated under reduced pressure to give the desired compound (54.9 g) as pale yellow powder.
The content as 10-(3'-aminopropyloxy)-7-ethyl-(20S)camptothecin hydrochloride was confirmed as 4.2 by absorption at 367.5 nm. According to the analysis by GPC (Gel Permeation Chromatograph), the average molecular weight of the desired product was 121 kDa, and the degree of distribution (Mw/Mn) was 1.47.
Preparation 2 WO 03/015826 PCT/JP02/08309 26 Preparation of CM-dextran-13-[(2'R,3'S)-3'-N-tertbutoxycarbonyl-3'-phenyl-2'-O-L-phenylalanyl-glycyl-
III:
HO 0 OH NH-Boc CM-Dextran-Phe-Gly-O OH AcO Bzd (Bz is benzoyl group, hereinafter, the same) CM-Dextran(2008 mg, CM-degree: 0.47, the average molecular weight: 170 kDa) was dissolved with stirring in purified water (90 ml), and thereto were added 13- [(2'R,3'S)-3'-N-tert-butoxycarbonyl-3'-phenyl-2'-0-Lphenylalanyl-glycyl-isoserinyl]-10-deacyl-baccatin III mesylate (119 mg) and dimethylformamide (90 ml), and the mixture was stirred so as to dissolve. To the mixture was added with stirring 2-ethoxy-l(2H)-quinolinecarboxylic acid and the mixture was stirred at room temperature overnight. To the reaction solution was added ethanol (720 ml) with stirring, and thereto was further added dropwise 3M brine (1.8 ml) under stirring. The precipitates were collected by centrifugation, and dissolved in water (200 ml), and the pH value of the solution was adjusted to pH 7 with 0.2N aqueous sodium hydroxide solution. The solution was poured into ethanol (800 ml) with stirring, and thereto WO 03/015826 PCT/JP02/08309 27 was added dropwise 3M brine (4 ml) with stirring. The resulting precipitates were collected by centrifugation, and purified in the same manner as in Preparation to give the desired compound (600 mg) as white powder.
The content of the active substance: 2.4 %(UV method, (A 276 nm)) Preparation 3 Preparation of CM-dextran-2'-O-phenylalanyl-glycyl-taxol: AcO O OH NH-Bz CM-Dextran-Phe-Gly-O O OH AcO BzO CM-Dextran (1.294g, CM-degree: 0.47, the average molecular weight: 170 kDa) was dissolved with stirring in purified water (70 ml), and thereto were added 2'-O-phenylalanyl-glycyltaxol mesylate (77 mg) and dimethylformamide ml), and the mixture was further stirred so as to dissolve. 2-Ethoxy-1(2H)-quinolinecarboxylic acid (2.59 g) was added to the mixture under stirring, and the mixture was reacted with stirring overnight. The reaction solution was added to ethanol (700 ml) under stirring, and thereto was added dropwise 3M brine (1.4 ml) under stirring. The precipitates were collected by centrifugation, and dissolved in water (240 ml), and mixed with ethanol (1200 WO 03/015826 PCT/JP02108309 28 ml) under stirring. 3M Brine (4.8 ml) was added drowpise to the mixture under stirring for precipitation. In the same manner, the precipitation was further repeated three times to give the desired product (746 mg) as white powder.
The content of the active substance: 4.8 (UV method C 2 73 run) Preparation 4 Preparation of carboxymethyldextran-Polyalcohol (iS,9S) -1- (glycyl-glycyl-L-phenylalanyl-glycylamilo) fluoro-2, 3-dihydro-9-hydroxy-4-methyl-1H, 12H-benzo [de] pyrano 7]indoridino 2-b] quinoline-lO, 13 C9H,15) dione: Preparation of (iS, 9S) -1-(t-butoxycarbonyl-giycylqlycyl-L-phenylalanyl-glycylamino) -9-ethyl-5-f luoro-2, 3dihydro-9-hydroxy-4-methyl-lH, 12H-benzo [delpyrano- [3',4':6,7]indolidino[1,2-b]quinoline-lO,13(9H,l5H)-diole: Boc-Gly-Gly-Phe-Gly
H
5 C2 OH To a solution of (1S,9S)-l-amino-9-ethyl-5-fluoro-2,3dihydro-9-hydroxy-4-methyl--H, 12H-benzo [delpyrano- [3',4':6,7]indolidino[1,2-b]quinoline10,13C9H,15H)-dione hydrochloride (167 mg; 0.354 mmol), t-butoxycarbonyl- WO 03/015826 WO 03/15826PCT/1P02108309 29 glycy1-glycyl-L-phelalal-g1ycile (463 mug; 1.06 mmcl) and 1-hydroxybenzotriazole monohydrate (HOBT) (143 mug; 1.06 mmol) in dimethylformamide (DMF) (l0mi) were added l-(3dimethylaminopropyl) -3-ethylcarbodimimide (EDC) hydrochloride (270 mg; 1.42 mmol), triethylamine (148 iii; 1.06 inmol) and 4-dimethylaminopyridine (DMAP) (5 mtg; 0.04 mmol). The reaction mixture was stirred at room temperature for 15 hours, and the solvent was concentrated under reduced pressure. The residue was dissolved in chloroform, and the mixture was washed, dried, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (solvent; chloroform methanol 50:1 to 10:1) to give the title compound (228 mg, yield: 75 as pale yellow solid.
IR (Nujol) 3290, 1710, 1655 cnC 1 ESI-MS; 854 (M+H) Preparation of (lS,9S)-l-(glycyl-glycyl-L-phenylalanyl-glycylamino) -9-ethyl-5-fluoro-2, 3-dihydro-9-hydroxy- 4-methyl-lH,12H-benzo[delpyralo[3',4' :6,llindolidino[1,2b~quinoline-10,13(9H,15H)-dione: Gly-Gly-Phe-Gly
-HOI
WO 03/015826 PCT/JP02/08309 To a solution of (1S,9S)-1-(t-butoxycarbonyl-glycylglycyl-L-phenylalanyl-glycylamino)-9-ethyl-5-fluoro-2,3dihydro-9-hydroxy-4-methyl-1H,12H-benzo[de]pyrano- [3',4':6,7]indolidino[1,2-b]quinoline-10,13(9H,15H)-dione (220 mg; 0.258 mmol) in dioxane (4 ml) was added 4N hydrogen chloride solution in dioxane (6 ml) under stirring in an ice bath. The mixture was stirred at room temperature for 16 hours. Diethyl ether (30 ml) was added to the reaction mixture, and the mixture was stirred at room temperature for one hour. The precipitates were collected by filtration, and dried to give the title compound (176 mg, yield; 86 as yellow powder.
IR (Nujol); 3250, 1745, 1660, 1605, 1535 cm ESI-MS; 754 (M+H) Preparation of dextran polyalcohol (PA-Dextran): Acetic buffer (0.1 M, pH 5.5, 1000 ml) was put into a three-neck round bottom flask (capacity; 3 liters).
Dextran T-500® (10.0 g, manufactured by Amersham Pharmacia Biotech AB) was added in small portions to the buffer over a period of 30 minutes at room temperature. The mixture was stirred for about 30 minutes until the solution became clear, and then, the mixture was cooled at 5°C (inner temperature) in a bath.
Separately, to a flask (capacity; 1 liter) were added sodium periodate (33.0 g) and water (1000 ml), and the WO 03/015826 PCT/JP02/08309 31 mixture was s-tirred at room temperature, and then cooled at 0
C.
To the above dextran solution was added with stirring the above sodium periodate solution at 5°C, and the mixture was ketp at 5 0 C for 5 days in a dark place. The excess sodium periodate was removed by adding ethylene glycol ml), and the mixture was further stirred at 5 0 C for 2 hours.
The reaction mixture was cooled to 3 0 C, and thereto was added 8M aqueous sodium hydroxide solution during which the reaction temperature was kept below 6 0 C (the pH value of the reaction mixture became over pH To the reaction mixture was added sodium borohydride (14 g) in small portions with stirring, and the mixture was stirred at overnight. In order to remove the excess sodium borohydride, the pH value of the reaction mixture was adjusted to below pH 5.5 by adding acetic acid thereto at 3 to 6 0 C, and the mixture was further stirred for 2 hours.
The pH value of the reaction mixture was adjusted to about pH 7.8 with 8M aqueous sodium hydroxide solution. The mixture was subjected to dialysis against water (Spectora®/Por 3 membrane, Molecule weight cutoff <3500), and lyophilized to give dextran polyalcohol (8.34 g) as amorphous powder.
Preparation of carboxymethyldextran polyalcohol (CM- PA-Dextran): WO 03/015826 PCT/JP02/08309 32 Water (155 ml) was put into a three-neck round bottom flask (capacity; 500 ml), and thereto was added with stirring dextran polyalcohol (5.18 g) at room temperature over a period of 10 minutes. The mixture was stirred for about 10 to 30 minutes until the mixture became clear, and then sodium hydroxide (pellet, 97.0 21.8 g) was added to the dextran polyalcohol solution in small portions under stirring, during which the inner temperature was kept at to 40 0 C in an ice bath. The reaction flask was put in a bath, and the mixture was stirred at 30 0 C. Chloroacetic acid (31.1 g) was added with stirring in small portions into the reaction mixture at 30 to 40 0 C. After the addition, the mixture was further stirred at 30 0 C in a bath for 20 hours. The reaction mixture was cooled in an ice bath, and the mixture was neutralized by adding thereto acetic acid under stirring the pH value was adjusted to below pH 9).
Water (160 ml) was added to the mixture, and the mixture was subjected to dialysis against water (Spectora®/Por 3 membrane, Molecule weight cutoff <3500), and lyophilized to give carboxymethydextran polyalcohol (6.53 g) as amorphous powder.
Preparation of carboxymethyldextran-polyalcohol- (1S,9S)-1-(glycyl-glycyl-L-phenylalanyl-glycylamino)-9ethyl-5-fluoro-2,3-dihydro-9-hydroxy-4-methyl-lH,12H- WO 03/015826 PCT/JP02/08309 33 benzo[de]pyrano[3',4':6,7]indolidino[1,2-b]quinoline- 10,13(9H,15H)-dione: ml) was put into a round bottom flask (capacity; 100 ml), and thereto was added carboxymethyldextran polyalcohol (1.0g) at room temperature with stirring over a period of 5 minutes. The mixture was stirred about 30 minutes until the mixture became clear. A solution of (iS,9S)-1-(glycyl-glycyl-L-phenylalanylglycylamino)-9-ethyl-5-fluoro-2,3-dihydro-9-hydroxy-4methyl-lH,12H-benzo[de]pyrano[3',4':6,7]indolidino[1, 2 b]quinoline-10,13(9H,15H)-dione in dimethylformamide (100 ml) was added with stirring to the mixture, and further added thereto dimethylformamide (15 ml), and the mixture was stirred for 10 minutes. To the mixture was added dropwise with stirring a solution of 2-ethoxy-lethoxycarbonyl-1,2-dihydroquinoline (EEDQ) in dimethylformamide (1.0 g/10 ml) at room temperature, and the mixture was further stirred for 18 hours. The reaction mixture was subjected to dialysis against water (Spectora®/Por 3 membrane, Molecule weight cutoff <3500), and further purified by cation exchange column (BioRad AG® column, Na-type, 30 ml). The main fraction was subjected to dialysis (Spectora®/Por 3 membrane, Molecule weight cutoff <3500), and lyophilized to give a crude product, which was pulverized with acetone, collected by filtration, and dried to give the desired product (904 mg) as pale yellow powder.
INDUSTRIAL APPLICABILITY The pharmaceutical composition of the present invention may highly accumulate at the site such as lymph node or the liver to which cancers may spread, and suppressively act on the growth of tumor cells without affecting on the normal cells, and hence, the pharmaceutical composition of the present invention is useful in the inhibition of metastasis, particularly in the inhibition of lymph node metastasis or liver metastasis, or prevention of reoccurrence of a malignant tumor.
In addition, the present pharmaceutical composition may exhibit its effects not only before the onset of metastasis but also after the onset of metastasis.
Therefore, the present pharmaceutical composition is also useful in the inhibition of metastasis or prevention of reoccurrence of a malignant tumor after topical therapy surgery, radiation therapy, thermotherapy,.
cryotherapy, laser burning therapy, etc.).
Throughout the description and claims of this specification, the word "comprise" and variations of the word, such as "comprising" and "comprises", is not intended to exclude other additives, components, integers or steps.
Claims (15)
- 2. The pharmaceutical. composition according to claim 1, wherein the active substance having an anti-tumor activity is a camptothecin derivative of the formula R1 x T< HSC2 OH wherein R is a substituted or unsubstituted lower alkyl group,- X 1 is a group of the formula: -NHRz (R is a hydrogen atom or a lower-alkyl group) and-Alk is a straight-chain or branched chain C, alkylene group having optionally an oxygen atom in the chain thereof, or a compound of the formula (II): WO 03/015826 PCT/JP02/08309 36 R 3 R 2 0 N O 11 R N O R H 5 C 2 OH wherein two groups of R 2 to R 6 being adjacent each other combine to form a lower alkylene group, and one of the carbon atoms of said lower alkylene group is substituted by an amino group, and the remaining three groups of R 2 to R 6 are a hydrogen atom, a lower alkyl group or a halogen atom.
- 3. The pharmaceutical composition according to claim 1 or claim 2, wherein the polysaccharide having a carboxyl group is a carboxy-C 1 4 alkyldextran or a carboxy-C 1 4 alkyldextran polyalcohol.
- 4. The pharmaceutical composition according to claim 1 or claim 2, wherein the polysaccharide having a carboxyl group is a carboxy-C 1 -4 alkyldextran. The pharmaceutical composition according to any one of claims 1, 2, 3 and 4, wherein the peptide is a member selected from the group consisting of glycyl-glycyl-L- or D-phenylalanyl-glycine, glycyl-glycine, glycyl-glycyl- glycine, glycyl-glycyl-glycyl-glycine, glycyl-glycyl- glycyl-glycyl-glycine, L- or D-phenylalanyl-glycine, L- or D-tyrosyl-glycine, L- or D-leucyl-glycine, L- or D- phenylalanyl-citrulline and L- or D-valyl-citrulline.
- 6. The pharmaceutical composition according to claim 1, wherein the polysaccharide having a carboxyl group is a carboxymethylated dextran, the active substance having an anti-tumor activity is 10-(3'-aminopropyloxy)-7-ethyl- and the peptide is glycyl-glycyl- glycine.
- 7. The pharmaceutical composition according to claim 1, wherein the polysaccharide having a carboxyl group is a carboxy-C,. 4 alkyldextran polyalcohol, the active substance having an anti-tumor activity is (1S, 9S)-1-amino-9-ethyl- 5-fluoro-2,3-dihydro-9-hydroxy-4-methyl-lH,12H-benzo[de]- pyrano[3',4' :6,7]indolidino[1,2-b]quinoline-10,13(9H,15H)- dione, and the peptide is glycyl-glycyl-L- or D-phenyl- alanyl-glycine.
- 8. The pharmaceutical composition according to any one of claims 1 to 7, which is a pharmaceutical composition for inhibiting the metastasis of a malignant tumor.
- 9. The pharmaceutical composition according to any one of claims 1 to 7, which is a pharmaceutical composition for oreventing the recurrence of a malignant tumor.
- 10. A method for inhibiting the metastasis or preventing the recurrence of a malignant tumor in a patient, the method including the step of administering to the patient a therapeutically effective amount of a composition which comprises as the active ingredient a polysaccharide derivative comprising a polysaccharide having a carboxyl group bound to an active substance having an anti-tumor activity via an amino acid or a peptide consisting of 2 to 8 amino acids which are the same or different, or a salt thereof.
- 11. The method of claim 10 wherein the active ingredient comprises a camptothecin derivative of the formula R I O N X'-Alk-O- (I) N 0 H 5 C2 OH 00 Swherein in R 1 is a substituted or unsubstituted lower alkyl group, X 1 is a group of the formula: -NHR 2 (R 2 is a hydrogen atom or a lower alkyl group) and Alk is a straight chain or branched chain C1-6 alkylene group having optionally an oxygen atom in the chain thereof, or a compound of the formula (II): R 3 R 2 0 R NO R N R HsC5 C OH wherein two groups of R2 to R 6 being adjacent to each other combine to form a lower alkylene group, and one of the carbon atoms of said lower alkylene group is substituted by an amino group, and the remaining three groups of R 2 to R 6 are a hydrogen atom, a lower alkyl group or a halogen atom.
- 12. The method of claim 10 or 11 wherein the polysaccharide having a carboxyl group is a carobxy-C 1 -4 alklydextran or a carboxy-Ci- 4 alkyldextran polyalcohol.
- 13. The method of claim 10 or 11 wherein the polysaccharide having a carboxyl group is a carboxy-Ci- 4 alkyldextran.
- 14. The method of any one of claims 10 to 13 wherein the peptide is a member selected from the group consisting of 0 glycyl-glycyl-L- or D-phenylalanyl-glycine, glycyl- Sglycine, glycyl-glycyl-glycine, glycyl-glycyl-glycyl- glycine, glycyl-glycyl-glycyl-glycyl-glycine, L- or D- phenylalanyl-glycine, L- or D-tyrosyl-glycine, L- or D- leucyl-glycine, L- or D-phenylalanyl-citrulline and L- or CD-valyl-citrulline. The method of claim 10 wherein the polysaccharide 00 Cl having a carboxyl group is a carboxymethylated dextran, the Cl active substance having an anti-tumor activity is 10-(3'- 0 10 aminopropyloxy)-7-ethyl-(20S)-camptothecin, and the peptide is glycyl-glycyl-glycine.
- 16. The method of claim 10 wherein the polysaccharide having a carboxyl group is a carboxy-Cl-4 alkyldextran polyalcohol, the active substance having an anti-tumor activity is (IS, 9S)-1-amino-9-ethyl-5-fluoro-2,3-dihydro- 9-hydroxy-4-methyl-lH,12H-benzso[de]- pyrano[3',4':6,7]indolidino[1,2-b]quinoline-10,13(9H,15H)- dione, and the peptide is glycyl-glycyl-L- or D-phenyl- alanyl-glycine.
- 17. The method of any one of claims 10 to 16, wherein the method is a method for inhibiting the metastasis of a malignant tumor.
- 18. The method of any one of claims 10 to 16, wherein the method is a method for preventing the recurrence of a malignant tumor.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001249717 | 2001-08-21 | ||
| JP2001-249717 | 2001-08-21 | ||
| PCT/JP2002/008309 WO2003015826A1 (en) | 2001-08-21 | 2002-08-16 | Pharmaceutical compositions comprising polysaccharide conjugates for inhibiting the metastsis or preventing the recurrence of maligant tumor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2002328093A1 AU2002328093A1 (en) | 2003-05-29 |
| AU2002328093B2 true AU2002328093B2 (en) | 2005-05-05 |
Family
ID=19078678
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002328093A Ceased AU2002328093B2 (en) | 2001-08-21 | 2002-08-16 | Pharmaceutical compositions comprising polysaccharide conjugates for inhibiting the metastsis or preventing the recurrence of maligant tumor |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP1418947A1 (en) |
| KR (1) | KR20040027972A (en) |
| CN (1) | CN100372570C (en) |
| AR (1) | AR035137A1 (en) |
| AU (1) | AU2002328093B2 (en) |
| BR (1) | BR0212036A (en) |
| CA (1) | CA2457056C (en) |
| HU (1) | HUP0401351A3 (en) |
| IL (1) | IL160148A0 (en) |
| MX (1) | MXPA04001599A (en) |
| NO (1) | NO20041194L (en) |
| NZ (1) | NZ530947A (en) |
| PL (1) | PL368319A1 (en) |
| RU (1) | RU2275913C2 (en) |
| TW (1) | TWI313609B (en) |
| UA (1) | UA75450C2 (en) |
| WO (1) | WO2003015826A1 (en) |
| ZA (1) | ZA200400917B (en) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200306314A (en) * | 2002-04-16 | 2003-11-16 | Tanabe Seiyaku Co | Liquid preparation comprising camptothecin derivative and pharmaceutical composition producible by lyophilizing the preparation |
| FR2914305B1 (en) * | 2007-03-29 | 2009-07-03 | Proteins & Peptides Man | DEXTRAN FUNCTIONALIZED BY HYDROPHOBIC AMINO ACIDS |
| ES2672201T3 (en) | 2008-07-16 | 2018-06-13 | Children's Medical Center Corporation | Imitation device of organs with microchannels and methods of use |
| KR101970634B1 (en) | 2011-06-02 | 2019-04-19 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | Methods and uses for ex vivo tissue culture systems |
| PL221351B1 (en) | 2012-03-14 | 2016-03-31 | Politechnika Warszawska | Method for obtaining polysaccharide nanoparticles |
| ES2671644T3 (en) * | 2012-10-11 | 2018-06-07 | Daiichi Sankyo Company, Limited | Antibody Conjugate - Drug |
| US9872924B2 (en) | 2012-10-19 | 2018-01-23 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate produced by binding through linker having hydrophilic structure |
| WO2015115091A1 (en) | 2014-01-31 | 2015-08-06 | 第一三共株式会社 | Anti-her2 antibody-drug conjugate |
| TWI718144B (en) | 2015-05-04 | 2021-02-11 | 美商輝瑞股份有限公司 | Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof |
| AU2016286898B2 (en) | 2015-06-29 | 2022-12-08 | Daiichi Sankyo Company, Limited | Method for selectively manufacturing antibody-drug conjugate |
| TW201828993A (en) | 2016-12-12 | 2018-08-16 | 日商第一三共股份有限公司 | Combination of antibody-drug conjugate and immune checkpoint inhibitor |
| KR102537651B1 (en) | 2017-01-17 | 2023-05-26 | 다이이찌 산쿄 가부시키가이샤 | Anti-GPR20 Antibodies and Anti-GPR20 Antibody-Drug Conjugates |
| TW202330036A (en) | 2017-05-15 | 2023-08-01 | 日商第一三共股份有限公司 | Manufacturing method of antibody-drug conjugates |
| KR20200041993A (en) | 2017-08-31 | 2020-04-22 | 다이이찌 산쿄 가부시키가이샤 | Method for improved production of antibody-drug conjugates |
| CN117838881A (en) | 2017-08-31 | 2024-04-09 | 第一三共株式会社 | New method for preparing antibody-drug conjugate |
| CN117815404A (en) | 2018-05-18 | 2024-04-05 | 第一三共株式会社 | anti-MUC 1 antibody-drug conjugates |
| CN109481691A (en) * | 2018-11-20 | 2019-03-19 | 珠海天香苑生物科技发展股份有限公司 | Gemcitabine-carboxymethyl polysaccharide conjugate, preparation method and its usage |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0640622A1 (en) * | 1993-02-26 | 1995-03-01 | Drug Delivery System Institute, Ltd. | Polysaccharide derivative and drug carrier |
| EP0757049A1 (en) * | 1995-08-02 | 1997-02-05 | Tanabe Seiyaku Co., Ltd. | Camptothecin derivatives |
| EP0781781A2 (en) * | 1995-12-28 | 1997-07-02 | Tanabe Seiyaku Co., Ltd. | Camptothecin derivatives |
| EP0895784A1 (en) * | 1996-04-15 | 1999-02-10 | Asahi Kasei Kogyo Kabushiki Kaisha | Medicament composite |
| EP0916348A1 (en) * | 1996-06-06 | 1999-05-19 | Daiichi Pharmaceutical Co., Ltd. | Drug complexes |
| EP1080732A1 (en) * | 1998-05-22 | 2001-03-07 | Daiichi Pharmaceutical Co., Ltd. | Drug composites |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1058038C (en) * | 1996-12-31 | 2000-11-01 | 中国科学院感光化学研究所 | Low contract photo-solidification cladding material, its prepn. method and use |
-
2002
- 2002-08-14 TW TW091118260A patent/TWI313609B/en not_active IP Right Cessation
- 2002-08-15 AR ARP020103077A patent/AR035137A1/en unknown
- 2002-08-16 BR BR0212036-4A patent/BR0212036A/en not_active IP Right Cessation
- 2002-08-16 CN CNB028163176A patent/CN100372570C/en not_active Expired - Fee Related
- 2002-08-16 CA CA002457056A patent/CA2457056C/en not_active Expired - Fee Related
- 2002-08-16 AU AU2002328093A patent/AU2002328093B2/en not_active Ceased
- 2002-08-16 EP EP02762786A patent/EP1418947A1/en not_active Withdrawn
- 2002-08-16 WO PCT/JP2002/008309 patent/WO2003015826A1/en active IP Right Grant
- 2002-08-16 RU RU2004108141/15A patent/RU2275913C2/en not_active IP Right Cessation
- 2002-08-16 NZ NZ530947A patent/NZ530947A/en not_active IP Right Cessation
- 2002-08-16 HU HU0401351A patent/HUP0401351A3/en unknown
- 2002-08-16 PL PL02368319A patent/PL368319A1/en not_active Application Discontinuation
- 2002-08-16 KR KR10-2004-7002566A patent/KR20040027972A/en not_active Application Discontinuation
- 2002-08-16 IL IL16014802A patent/IL160148A0/en unknown
- 2002-08-16 MX MXPA04001599A patent/MXPA04001599A/en unknown
- 2002-08-16 UA UA2004032071A patent/UA75450C2/en unknown
-
2004
- 2004-02-04 ZA ZA200400917A patent/ZA200400917B/en unknown
- 2004-03-19 NO NO20041194A patent/NO20041194L/en not_active Application Discontinuation
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0640622A1 (en) * | 1993-02-26 | 1995-03-01 | Drug Delivery System Institute, Ltd. | Polysaccharide derivative and drug carrier |
| EP0757049A1 (en) * | 1995-08-02 | 1997-02-05 | Tanabe Seiyaku Co., Ltd. | Camptothecin derivatives |
| EP0781781A2 (en) * | 1995-12-28 | 1997-07-02 | Tanabe Seiyaku Co., Ltd. | Camptothecin derivatives |
| EP0895784A1 (en) * | 1996-04-15 | 1999-02-10 | Asahi Kasei Kogyo Kabushiki Kaisha | Medicament composite |
| EP0916348A1 (en) * | 1996-06-06 | 1999-05-19 | Daiichi Pharmaceutical Co., Ltd. | Drug complexes |
| EP1080732A1 (en) * | 1998-05-22 | 2001-03-07 | Daiichi Pharmaceutical Co., Ltd. | Drug composites |
Also Published As
| Publication number | Publication date |
|---|---|
| NO20041194L (en) | 2004-03-19 |
| BR0212036A (en) | 2004-08-17 |
| AR035137A1 (en) | 2004-04-14 |
| EP1418947A1 (en) | 2004-05-19 |
| NZ530947A (en) | 2006-04-28 |
| CN1545423A (en) | 2004-11-10 |
| HUP0401351A2 (en) | 2004-12-28 |
| CA2457056A1 (en) | 2003-02-27 |
| ZA200400917B (en) | 2004-08-25 |
| CA2457056C (en) | 2008-07-22 |
| RU2275913C2 (en) | 2006-05-10 |
| CN100372570C (en) | 2008-03-05 |
| IL160148A0 (en) | 2004-07-25 |
| PL368319A1 (en) | 2005-03-21 |
| WO2003015826A1 (en) | 2003-02-27 |
| RU2004108141A (en) | 2005-04-20 |
| HUP0401351A3 (en) | 2011-02-28 |
| KR20040027972A (en) | 2004-04-01 |
| TWI313609B (en) | 2009-08-21 |
| UA75450C2 (en) | 2006-04-17 |
| MXPA04001599A (en) | 2004-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002328093B2 (en) | Pharmaceutical compositions comprising polysaccharide conjugates for inhibiting the metastsis or preventing the recurrence of maligant tumor | |
| US6436912B1 (en) | Drug complexes | |
| US5892043A (en) | Camptothecin derivatives | |
| EP0955064B1 (en) | Process for producing drug complexes | |
| AU2002328093A1 (en) | Pharmaceutical compositions comprising polysaccharide conjugates for inhibiting the metastsis or preventing the recurrence of maligant tumor | |
| JP4717016B2 (en) | O, O'-amidmalonate and N, O-amidmalonate platinum complexes | |
| JP2018512376A (en) | Antibody drug conjugate | |
| JPS6259715B2 (en) | ||
| JP6957629B2 (en) | Non-linear self-destructive linker and its conjugate | |
| KR20180090290A (en) | Conjugates of Quaternized Tubular Compounds | |
| JPH1192405A (en) | Medicinal complex | |
| US20060052288A1 (en) | Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor | |
| JPH1171280A (en) | Medicine composition | |
| KR20170091610A (en) | Novel peg derivative | |
| EP3071238B1 (en) | Conjugate comprising indole-3-carbinol for medical use | |
| JP2003137818A (en) | Composition for metastasis control or recurrence prevention of carcinoma | |
| JP3322203B2 (en) | Pharmaceutical composition | |
| KR20000016371A (en) | Process for producing drug complexes | |
| IE20070508A1 (en) | Medicaments with effect on brain metastases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |